
ARPA-H Launches Two New Programs
EMBODY: Engineering of Immune Cells Inside the Body
The goal of EMBODY is to radically alter how immune therapies are developed and delivered for life-threatening and chronic conditions by retraining healthy immune cells, and eliminating time, cost and access hurdles.
“By developing agents that target specific immune cell types, essentially providing instructions to cells already active inside your body, we hope to make advanced immunotherapies available close to home for Americans across the country,” said EMBODY Program Manager Daria Fedyukina, Ph.D., in ARPA-H’s recent program announcement.
PRINT (Personalized Regenerative Immunocompetent Nanotechnology Tissue)
PRINT intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on organs that will not require immunosuppressive drugs.
“By starting from multiple different types of cells, we will be creating organs that will be individually matched,” said PRINT Program Manager Ryan Spitler, Ph.D., in ARPA-H’s recent program announcement. “The body will not recognize it as a foreign entity, eliminating the need of immunosuppressive drugs, which has never been done in the history of organ transplantation.”
To learn more about both programs, including how to register for the upcoming Proposers’ Days, visit the EMBODY program page and PRINT program page
- Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
… immunology. "The addition of Dr. Chan elevates the scientific perspective of our Board as we continue to identify and advance opportunities for … - AbbVie's US$1.4b AI-Powered Campus Reshapes Immunology And Neuroscience Story
The facility will use advanced technologies and AI to support global production of immunology, neuroscience, and oncology medicines. The project … - Earlier Biologics Initiation Tied to Fewer Severe Pediatric Asthma Exacerbations
Allergy & Immunology; >. Earlier Biologics Initiation Tied to Fewer … Related Posts. Pediatric Asthma Medication Use Drops Nearly 7% After Public … - Gut microbiota impacts resistance to bacterial pneumonia: Study | EurekAlert!
Goodpasture Professor of Pathology; director of the Vanderbilt Institute for Infection, Immunology and Inflammation; and co-corresponding author of … - Review CRAC channels as targets for immunotherapy – ScienceDirect.com
Current Opinion in Immunology · Volume 100, June 2026, 102780. Current Opinion in Immunology. Review. CRAC channels as targets for immunotherapy.

